https://ojs.bbwpublisher.com/index.php/DH <p style="text-align: justify;"><em>Dermatological Health</em> is a peer-reviewed, open access journal that publishes original research articles and review articles related to the prevention, diagnosis, and treatment of disorders of the skin, hair, and nails. The covered topics include, but are not limited to:&nbsp;clinical, investigative, and population-based studies, healthcare delivery and quality of care research,&nbsp;high quality, cost effective, and innovative treatments,&nbsp;new diagnostic techniques, and&nbsp;other topics related to the prevention, diagnosis, and treatment of disorders of the skin, hair, and nails.&nbsp;Each issue includes continuing medical education articles designed to fill practice and knowledge gaps in the delivery of dermatologic care.&nbsp;</p> Bio-Byword Scientific Publishing PTY LTD en-US Dermatological Health 2981-8206 https://ojs.bbwpublisher.com/index.php/DH/article/view/8512 <p><em>Objective</em>: To analyze the clinical effect of transconjunctival lower eyelid blepharoplasty for the treatment of lower eye bags. <em>Methods</em>: Retrospective analysis was done on 50 cases of patients with lower eye bags admitted to the hospital from August 2022 to August 2023. The control group received transcutaneous lower eyelid blepharoplasty, while the observation group received transconjunctival lower eyelid blepharoplasty. The efficacy, surgical indexes, and the difference in complications of the two groups were compared. <em>Results</em>: The efficacy of the observation group was higher than that of the control group (<em>P</em> &lt; 0.05); the surgical time and postoperative skin recovery time of the observation group were shorter than that of the control group (<em>P</em> &lt; 0.05); the rate of postoperative complications after blepharoplasty in the observation group was lower than that in the control group (<em>P</em> &lt; 0.05). <em>Conclusion</em>: Transconjunctival lower eyelid blepharoplasty for the treatment of lower eye bags is safe and effective, which is favorable to the recovery of patients’ skin appearance.</p> Guanghui Wang Copyright (c) 2024 Author(s) 2024-10-15 2024-10-15 2 3 1 7 10.26689/dh.v2i3.8512 https://ojs.bbwpublisher.com/index.php/DH/article/view/7611 <p><span style="font-weight: 400;">Nanocellulose is a biodegradable nanomaterial derived from lignocellulosic biomass through mechanical, chemical, or enzymatic defibrillation processes to convert wood fibers into nanofibrils. This material consists of a network of cellulosic fibrils with a wide range of diameters, offering unique properties suitable for various functional applications. Nanocellulose can act as a substrate or coating, serving as an eco-friendly alternative to synthetic plastics. Despite having good barrier properties and strong mechanical strength, nanocellulose films are still not as effective as synthetic plastics. They are used in creating barrier materials, flexible electronics, and coatings for paper products.&nbsp;</span></p> Kirubanandan Shanmugam Copyright (c) 2024 Author(s) 2024-09-30 2024-09-30 2 3 8 33 10.26689/dh.v2i3.7611 https://ojs.bbwpublisher.com/index.php/DH/article/view/8494 <p>This study aims to investigate the expression variation, biological significance, and prognostic value of cyclin-dependent kinase inhibitor 2A (<em>CDKN2A</em>) as a common biomarker across 33 malignancies. Various bioinformatics tools, including UALCAN, GEPIA2, OncoDB, cBioPortal, TIMER2, STRING, DAVID, and the GSCA database, were employed for this pan-cancer analysis. The results revealed significant up-regulation of <em>CDKN2A</em> in 24 major human cancer subtypes (<em>P</em> &lt; 0.05). This up-regulation was strongly associated with poor overall survival and tumor dissemination, particularly in uterine corpus endometrial carcinoma (UCEC), colon adenocarcinoma (COAD), and liver hepatocellular carcinoma (LIHC), highlighting its potential as a prognostic biomarker. Moreover, <em>CDKN2A</em> overexpression was linked to diverse clinicopathological characteristics of patients. Genetic alterations recorded via cBioPortal indicated minimal mutation rates in COAD, LIHC, and UCEC. Additionally, promoter methylation, drug sensitivity, and enrichment analyses were performed to explore associations with <em>CDKN2A</em> expression. Overall, the findings emphasize the potential of <em>CDKN2A</em> as a shared diagnostic and prognostic biomarker, as well as a therapeutic target in COAD, LIHC, and UCEC, particularly in patients with varied clinicopathological traits.</p> Syed Hussain Raza Akbar Ali Copyright (c) 2024 Author(s) 2024-10-15 2024-10-15 2 3 34 46 10.26689/dh.v2i3.8494